SCHEMBL1228596

SCHEMBL1228596

Cc1cccnc1CCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29896207 1.00
Hydrochloric Acid SCHEMBL507827 0.98 NOS3 (0.45)
Hydrochloric Acid SCHEMBL29674692 0.98 NOS3 (0.45)
Hydrochloric Acid SCHEMBL23530500 0.98 NOS3 (0.45)
SCHEMBL28822555 0.79
SCHEMBL91425 0.79
SCHEMBL11702390 0.77
SCHEMBL14546317 0.77
SCHEMBL243610 0.77
SCHEMBL661300 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed
US-12281101-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2025-04-22 US disclosed
EP-4219463-B1 TERPYRIDINE DIKETONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHENZHEN SALUBRIS PHARM CO LTD (CN) 2025-01-15 EP disclosed
US-20240368133-A1 Compounds for the Treatment of Pain, in Particular, Neuropathic Pain, and/or Other Diseases or Disorders that are Associated with AT2R and/or AT2R Mediated Signaling CONFO THERAPEUTICS N.V. (BE) 2024-11-07 US disclosed
US-20240360140-A1 FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2024-10-31 US disclosed
CN-118159530-A Compounds for the treatment of pain, in particular neuropathic pain and/or other diseases or disorders associated with AT2R and/or AT2R mediated signalling 康福治疗有限公司 2024-06-07 CN disclosed
EP-4377307-A1 COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING Confo Therapeutics N.V. (BE) 2024-06-05 EP disclosed
US-11999716-B2 WDR5 inhibitors and modulators VANDERBILT UNIVERSITY (US) 2024-06-04 US disclosed
US-11999740-B2 Fused pyrazine derivatives as A2A / A2B inhibitors INCYTE CORPORATION (US) 2024-06-04 US disclosed
US-20240166627-A1 Terpyridinedione compound or salt thereof, and preparation method and application thereof SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2024-05-23 US disclosed
CN-85103357-A The method for making of tricyclic imidazole derivatives and acid salt thereof 1986-11-12 CN disclosed
US-4560693-A ANTISECRETORY, ANTIULCER AGENTS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1985-12-24 US disclosed
EP-0163842-A1 Tricyclic imidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1985-12-11 EP disclosed
US-4555518-A ANTIULCER AGENTS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1985-11-26 US disclosed
EP-0146370-A2 Imidazoquinolines containing other heterocyclic groups JOHN WYETH &amp; BROTHER LIMITED (GB) 1985-06-26 EP disclosed
EP-0134400-A2 Fluoroalkoxysubstituted pyridylmethylthio-(or sulfinyl-)benzimidazoles having a secretolytic activity Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1985-03-20 EP disclosed
EP-0127763-A1 Tricyclic ethers, process for their preparation, their use and medicaments containing them Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1984-12-12 EP disclosed
US-4173644-A HISTAMINE ANTAGONISTS, ANTIINFLAMMATORY AGENTS, ANTISECRETORY AGENTS SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-11-06 US disclosed
US-4171325-A Chemical process SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-10-16 US disclosed
US-4120966-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1978-10-17 US disclosed